Pleiotropy of PCSK9: Functions in Extrahepatic Tissues

Şener Y. Z., Tokgözoğlu L.

Current Cardiology Reports, vol.25, no.9, pp.979-985, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 25 Issue: 9
  • Publication Date: 2023
  • Doi Number: 10.1007/s11886-023-01918-2
  • Journal Name: Current Cardiology Reports
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.979-985
  • Keywords: Brain, Diabetes, Heart, Kidney, PCSK9
  • Hacettepe University Affiliated: Yes


Purpose of Review: Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in the metabolism of LDL receptors and mainly acts in the liver. However, there are accumulating data that PCSK9 involves in several functions in different organs beyond the liver. Herein we aimed to summarize the effects of PCSK9 in tissues other than the liver. Recent Findings: PCSK9 has crucial roles in heart, brain and kidney in addition to the cholesterol metabolism. Targeting PCSK9 for the treatment of hypercholesterolemia is effective in the prevention from cardiovascular diseases and PCSK9 inhibitors are getting to be administered in more cases. Therefore understanding the effects of PCSK9 in other tissues gained importance in the use of PCSK9 inhibitors era. Summary: PCSK9 participates in cardiac, renal, and neurologic functions however, current literature reveals that use of PSCSK9 inhibitors have beneficial or neutral effects on these organs. Inhibition of PCSK9 is assigned to be associated with new onset diabetes in experimental studies whereas real world data with PCSK9 inhibitors established no relationship between PCSK9 inhibitors and new onset diabetes. PCSK9 might be used as a target for the treatment of nephrotic syndrome and heart failure in the future.